Edition:
United States

Alk Abello A/S (ALKb.CO)

ALKb.CO on Copenhagen Stock Exchange

940.00DKK
10:59am EDT
Change (% chg)

kr.8.00 (+0.86%)
Prev Close
kr.932.00
Open
kr.931.00
Day's High
kr.942.00
Day's Low
kr.931.00
Volume
6,116
Avg. Vol
18,178
52-wk High
kr.1,300.00
52-wk Low
kr.732.00

Latest Key Developments (Source: Significant Developments)

Alk Abello Q2 EBIT DKK 119 million, beats expectations
Tuesday, 16 Aug 2016 02:04am EDT 

Alk Abello A/S : Q2 total revenue 773 million Danish crowns ($116.5 million)(Reuters poll 688 million crowns) . Q2 EBIT 119 million crowns (Reuters poll 88.6 million crowns) . Updated guidance to reflect H1 2016 performance and a higher than expected order intake in Europe . Guidance assumes 5-10 pct organic growth in base business in H2 2016 and a minor contribution from partnerships . Free cash flow is now expected at 50-100 million crowns (previously better than in 2015) . Full-year revenue in base business is now expected to grow organically by approximately 20 pct (previously: 15 pct) . Full-year revenue is now projected to exceed 2.9 billion crowns .Full-year EBITDA is now expected to exceed 600 million crowns before special items.  Full Article

Merck plans to end partnership agreement with Alk Abello
Wednesday, 27 Jul 2016 01:25am EDT 

Alk Abello A/S : Said on Tuesday MSD (known as Merck in the United States and Canada) had informed ALK of its plans to end their partnership agreement . Said all rights to GRASTEK, RAGWITEK and investigational house dust mite SLIT-tablets for USA, Canada and Mexico to revert to ALK at no fee following six- month transition period . Ongoing registration processes for investigational HDM SLIT-tablet will continue . North America remains major business opportunity and ALK will now undertake full strategic analysis before deciding on revised strategy . Transaction has no impact on ALK's full-year outlook for 2016 .Acting CEO and Chairman Steen Riisgaard said: "The timing of this move is unexpected".  Full Article

Alk Abello: Member of Management Board sells shares worth DKK 2.7 million
Friday, 20 May 2016 09:48am EDT 

Alk Abello A/S :Flemming Pedersen, Member of Board of Management, sold on May 20 a total of 2,191 Alk Abello shares at market value 2.7 million Danish crowns ($407,689).  Full Article

ALK-Abello names Carsten Hellmann new CEO
Wednesday, 18 May 2016 12:59am EDT 

ALK-Abello A/S : Said on Tuesday Board of Directors had appointed Carsten Hellmann as new President and Chief Executive . Hellmann is currently CEO of Merial and Executive Vice President and member of the Executive Committee of Sanofi .Hellmann to take up CEO position no later than Jan. 1, 2017.  Full Article

Alk Abello raises FY 2016 outlook
Wednesday, 4 May 2016 01:45am EDT 

Alk Abello A/S:Says updates FY 2016 guidance to reflect better than expected performance in Q1 and slightly clearer view of unfolding market situation in Europe.Says FY 2016 EBITDA is now expected to increase to around 575 million crowns (previously: about 450 million crowns) before special items, additional sales royalties and milestone payments.Says FY 2016 base business revenue now seen to grow organically by about 15 percent in local currencies to around 2.75 billion crowns (previous expectation: 10 percent growth and revenue of about 2.6 billion crowns).  Full Article

Alk Abello CEO Jens Bager steps down
Monday, 22 Feb 2016 11:07am EST 

Alk Abello A/S:Alk's CEO Jens Bager steps down.‍Search for a new CEO will be initiated immediately​.  Full Article

Alk Abello A/S gives FY 2016 guidance, proposes FY 2015 dividend
Tuesday, 9 Feb 2016 02:30am EST 

Alk Abello A/S:Partnerships are expected to further contribute to revenue and earnings, potential milestone payments in FY 2016-17 total 75 million​ Danish crowns ‍.Sees FY 2016 base business revenue to grow organically by about 10 pct to 2.6 billion​ crowns.Sees FY 2016 ‍EBITDA ex. items, ex. revenues from sales royalties and milestone payments, to increase by about 35 pct to 450 million crowns.Proposes dividend of ‍5 crowns per share​ for FY 2015​.  Full Article

Alk Abello A/S expands partnership into South-East Asian growth markets
Thursday, 28 Jan 2016 02:30am EST 

Alk Abello A/S:Expands partnership into South-East Asian growth markets​.Abbott will register and sell house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet in 7 new growth markets in SE Asia​.Agreement is expected to have a positive, long-term effect on Alk's financial results.Deal not expected to have a material impact on 2016 financial results​.  Full Article

Alk Abello A/S: Marketing authorisation for Acarizax issued in France
Wednesday, 27 Jan 2016 04:00am EST 

Alk Abello A/S:Authorities in France have issued a marketing authorisation for ALK's new house dust mite sublingual allergy immuno-therapy tablet (slit-tablet), Acarizax​.  Full Article

Alk Abello announces results from GRAZAX Asthma Prevention trial in children
Thursday, 14 Jan 2016 11:05am EST 

Alk Abello A/S:Announces top-line results from the five-year landmark GRAZAX Asthma Prevention (GAP) trial in children.Says trial did not show an effect in terms of time to first diagnosis of reversible impairment of lung function.Trial demonstrated that GRAZAX treatment significantly reduced the proportion of children experiencing asthma symptoms or using asthma medication.Says this effect sustained two years after end of treatment.Trial confirmed that GRAZAX treatment significantly reduced allergic rhinoconjunctivitis symptoms.Says this effect sustained two years after end of treatment.  Full Article

BRIEF-Alk Abello Q2 EBIT DKK 119 million, beats expectations

* Q2 total revenue 773 million Danish crowns ($116.5 million)(Reuters poll 688 million crowns)